Beam Therapeutics Inc
BEAM25.390USD
-0.930-3.53%
Fechamento 10/10, 16:00（ET）Cotações atrasadas em 15 min
2.56BValor de mercado
PerdaP/L TTM
Mais detalhes de Beam Therapeutics Inc Empresa
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Informações de Beam Therapeutics Inc
Código da empresaBEAM
Nome da EmpresaBeam Therapeutics Inc
Data de listagemFeb 06, 2020
CEOMr. John M. Evans
Número de funcionários483
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 06
Endereço238 Main Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone18573278775
Sitehttps://beamtx.com/
Código da empresaBEAM
Data de listagemFeb 06, 2020
CEOMr. John M. Evans
Executivos da empresa Beam Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Detalhamento da receita
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
8.47M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
12.38%
ARK Investment Management LLC
10.29%
Farallon Capital Management, L.L.C.
9.90%
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
6.64%
Outro
51.21%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
12.38%
ARK Investment Management LLC
10.29%
Farallon Capital Management, L.L.C.
9.90%
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
6.64%
Outro
51.21%
Tipos de investidores
Investidores
Proporção
Investment Advisor
55.19%
Hedge Fund
20.88%
Investment Advisor/Hedge Fund
19.46%
Venture Capital
4.81%
Research Firm
3.80%
Individual Investor
1.27%
Bank and Trust
0.67%
Pension Fund
0.28%
Family Office
0.06%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
528
106.40M
105.18%
+1.16M
2025Q2
537
101.17M
100.03%
+11.84M
2025Q1
562
100.13M
99.59%
+12.37M
2024Q4
542
80.18M
95.83%
-6.23M
2024Q3
539
78.60M
95.42%
-7.95M
2024Q2
538
78.23M
95.09%
-5.21M
2024Q1
550
76.09M
93.23%
-4.97M
2023Q4
549
75.48M
92.79%
-3.23M
2023Q3
554
74.84M
95.14%
-3.35M
2023Q2
566
72.06M
94.81%
-2.24M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
12.53M
12.38%
+4.93M
+64.83%
Jun 30, 2025
ARK Investment Management LLC
10.41M
10.29%
+1.56M
+17.66%
Jul 31, 2025
Farallon Capital Management, L.L.C.
10.01M
9.9%
+85.00K
+0.86%
Jun 30, 2025
The Vanguard Group, Inc.
9.69M
9.58%
+837.64K
+9.47%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.72M
6.64%
-37.63K
-0.56%
Jun 30, 2025
Amova Asset Management Co., Ltd.
4.73M
4.68%
+462.57K
+10.84%
Jun 30, 2025
ARCH Venture Partners
4.54M
4.49%
--
--
Jun 30, 2025
State Street Global Advisors (US)
3.64M
3.6%
+198.15K
+5.76%
Jun 30, 2025
Bellevue Asset Management AG
2.89M
2.86%
+493.36K
+20.59%
Jun 30, 2025
Kynam Capital Management LP
2.42M
2.39%
-100.52K
-3.99%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: seg, 6 de out
Atualizado em: seg, 6 de out
Nome
Proporção
ARK Genomic Revolution ETF
3.21%
ARK Innovation ETF
1.71%
WisdomTree BioRevolution Fund
1.69%
Global X Genomics & Biotechnology ETF
1.68%
Virtus LifeSci Biotech Clinical Trials ETF
0.73%
Franklin Genomic Advancements ETF
0.53%
SPDR S&P Biotech ETF
0.49%
Direxion Daily S&P Biotech Bull 3X Shares
0.3%
Invesco Nasdaq Biotechnology ETF
0.17%
ProShares Ultra Nasdaq Biotechnology
0.17%
Ver Mais
ARK Genomic Revolution ETF
Proporção3.21%
ARK Innovation ETF
Proporção1.71%
WisdomTree BioRevolution Fund
Proporção1.69%
Global X Genomics & Biotechnology ETF
Proporção1.68%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.73%
Franklin Genomic Advancements ETF
Proporção0.53%
SPDR S&P Biotech ETF
Proporção0.49%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.3%
Invesco Nasdaq Biotechnology ETF
Proporção0.17%
ProShares Ultra Nasdaq Biotechnology
Proporção0.17%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
